-
Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
-
Ramit Mahajan, Arshdeep Singh, Saurabh Kedia, Kirandeep Kaur, Vandana Midha, Pabitra Sahu, Varun Mehta, Dharmatma Singh, Namita Bansal, Khushdeep Dharni, Sandeep Kaushal, Vineet Ahuja, Ajit Sood
-
Intest Res. 2022;20(1):64-71. Published online February 3, 2021
-
-
Full text PubReader ePub Crossref - TDM PDF
-
Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
-
Shin Ju Oh, Ga Young Shin, Hosim Soh, Jae Gon Lee, Jong Pil Im, Chang Soo Eun, Kang-Moon Lee, Dong Il Park, Dong Soo Han, Hyo Jong Kim, Chang Kyun Lee
-
Intest Res. 2021;19(3):323-331. Published online August 18, 2020
-
-
Full text PubReader ePub Crossref - TDM PDF
- IBD
-
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
-
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chian Lim, Wai Keung Leung, Raja Affendi Raja Ali, Deng Chyang Wu, Evan Ong, Nazri Mustaffa, Julajak Limsrivilai, Tadakazu Hisamatsu, Suk Kyun Yang, Qin Ouyang, Richard Geary, Janaka H De Silva, Rungsun Rerknimitr, Marcellus Simadibrata, Murdani Abdullah, Rupert WL Leong, the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis
-
Intest Res. 2019;17(3):285-310. Published online May 31, 2019
-
-
Full text PubReader ePub Crossref - TDM PDF
-
Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
-
Rintaro Moroi, Katsuya Endo, Katsutoshi Yamamoto, Takeo Naito, Motoyuki Onodera, Masatake Kuroha, Yoshitake Kanazawa, Tomoya Kimura, Yoichi Kakuta, Atsushi Masamune, Yoshitaka Kinouchi, Tooru Shimosegawa
-
Intest Res. 2019;17(1):94-106. Published online December 3, 2018
-
-
Full text PubReader ePub Crossref - TDM PDF Supplementary Material
- IBD
-
Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
-
Akihiro Koga, Toshiyuki Matsui, Noritaka Takatsu, Yasumichi Takada, Masahiro Kishi, Yutaka Yano, Takahiro Beppu, Yoichiro Ono, Kazeo Ninomiya, Fumihito Hirai, Takashi Nagahama, Takashi Hisabe, Yasuhiro Takaki, Kenshi Yao, Hirotsugu Imaeda, Akira Andoh
-
Intest Res. 2018;16(2):223-232. Published online April 30, 2018
-
-
Full text PubReader ePub Crossref - TDM PDF Supplementary Material
-
Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
-
Jang Wook Lee, Chang Hwan Choi, Ji Hoon Park, Jeong Wook Kim, Sang Bum Kang, Ja Seol Koo, Young-Ho Kim, You Sun Kim, Young Eun Joo, Sae Kyung Chang
-
Intest Res. 2016;14(2):146-151. Published online April 27, 2016
-
-
Full text PubReader ePub Crossref - TDM PDF
-
Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
-
Nam Hee Kim, Yoon Suk Jung, Chang Mo Moon, Shin Yeong Lee, Eun Ran Kim, Young Ho Kim, Chang Kyun Lee, Suck Ho Lee, Jae Hak Kim, Kyu Chan Huh, Soon Man Yoon, Hyun Joo Song, Sun-Jin Boo, Hyun Joo Jang, You Sun Kim, Kang-Moon Lee, Jeong Eun Shin, Dong Il Park
-
Intest Res. 2014;12(4):281-286. Published online October 27, 2014
-
-
Full text PubReader ePub Crossref - TDM PDF